DNLIDenali Therapeutics Inc.

$24.58

Who owns DNLI

265 institutions reported holding DNLI for 2026Q1, together 79% of the company, more than the 247 a quarter earlier.

265

Institutions reporting a position · as of 2026Q1 · up from 247 the quarter before

Shares held by institutions
147.4M

Shares held by institutions · 79% of the company · long US equity positions only, as reported on Form 13F

Reported value
$2.82B

Reported value · at 2026-03-31 prices, not today's

Top 5 holders
29%

Top 5 holders · of the whole company, between five filers

Details
Reporting quarter2026-03-31
2026Q1
Quarters on record
34
New positions
48
Positions exited
36
Added to
99
Reduced
54
Top 10 holdersof the company
42%
Institutional ownership by quarter, 2017Q4 to 2026Q1
QuarterFilersSharesReported value
2026Q1265147.4M$2.82B
2025Q4247151.1M$2.50B
2025Q3237135.5M$1.97B
2025Q2226137.6M$1.92B
2025Q1220135.9M$1.85B
2024Q4222127.9M$2.61B
2024Q3214126.7M$3.69B
2024Q2201123.9M$2.88B
2024Q1209122.4M$2.51B
2023Q4208115.0M$2.46B
2023Q3193108.6M$2.24B
2023Q2201108.0M$3.18B
2023Q1200108.0M$2.49B
2022Q4198105.9M$2.94B
2022Q319992.4M$2.84B
2022Q218792.7M$2.73B
Largest reported holders, 2026Q1
HolderShares% of companyValue
VANGUARD GROUP INC13.5M7.2%$258M
BlackRock Inc.13.0M7.0%$250M
BAILLIE GIFFORD & CO12.1M6.5%$232M
T. Rowe Price Investment Management, Inc.8.5M4.6%$164M
Temasek Holdings (Private) Ltd7.0M3.8%$135M
STATE STREET CORP6.3M3.4%$120M
FMR LLC4.6M2.5%$88M
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC4.4M2.4%$85M
GOLDMAN SACHS GROUP INC4.4M2.4%$85M
BAKER BROS. ADVISORS LP3.7M2.0%$72M

SEC Form 13F data sets (DERA bulk files). 13F is quarterly, filed up to 45 days late, and covers long US equity positions only, no shorts, no derivatives, nothing held below the reporting threshold.

reading the register…